Articles published by CEL-SCI Corporation

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

April 23, 2024

Tickers CVM

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

March 19, 2024

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Issues Letter to Shareholders

March 06, 2024

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

February 15, 2024

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

February 13, 2024

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

February 09, 2024

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

February 06, 2024

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

January 31, 2024

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

December 22, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

December 04, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

November 20, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

November 16, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Issues Letter to Shareholders

October 30, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals

October 24, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

October 23, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production

October 19, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

October 05, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer

September 26, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results

August 11, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Closing of Public Offering

July 20, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Pricing of Public Offering

July 17, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Proposed Public Offering of Common Stock

July 17, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer

July 14, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer

July 11, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed

June 22, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023

May 15, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results

May 12, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

April 27, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer

April 19, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension

March 08, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.